IN BRIEF: Syncona portfolio company sees "encouraging" early data

Fri, 10th Jun 2022 14:42

Syncona Ltd - London-based investor in healthcare companies - Announces that its portfolio company, Autolus Therapeutics PLC, has published new clinical data across multiple programmes. Autolus reports "positive" early safety and efficacy data from Auto4 in patients with T cell lymphoma and "encouraging" early safety and efficacy data from Auto1/22 in paediatric acute lymphoblastic leukaemia.

Current stock price: 196.00 pence, down 0.5% in London on Friday

12-month change: down 7.3%

By Heather Rydings; heatherrydings@alliancenews.com

Related Shares

More News

17 Jun 2024 13:15

Syncona to invest GBP40 million into newly created Spur Therapeutics

(Alliance News) - Syncona Ltd on Monday said it will provide further funding to a newly formed firm created after one of its portfolio companies acqui...

13 Jun 2024 16:05

UK earnings, trading statements calendar - next 7 days

17 May 2024 14:34

Syncona notes Autolus's first quarter loss widens amid higher costs

(Alliance News) - Syncona Ltd on Friday noted that Autolus Therapeutics PLC reported an increased loss amid higher operating costs.

9 May 2024 13:58

IN BRIEF: Syncona's Freeline gets positive results for Gaucher disease

Syncona Ltd on Thursday - London-based investor in healthcare companies - Says UK portfolio company Freeline Therapeutics Ltd presents positive new da...

9 May 2024 11:19

Syncona reports positive findings from investee Freeline

(Sharecast News) - Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phas...

Latest Share Chat